Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

Consent was added to this article: The patient provided consent (by signing on a consent document) at the time of tumor tissue and blood sample collection stating willingness to:

1. Provide the required sample for tumor molecular profiling.

2. Research use of deidentified data including publication of (deidentified) findings.

Original article: Oncotarget. 2020; 11:4358–4363. 4358-4363. https://doi.org/10.18632/oncotarget.27809